Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non –small cell lung cancer: A real-world multicentre study

The PACIFIC trial demonstrated that durvalumab therapy following chemoradiation (CRT) was associated with improved overall survival (OS) in patients with stage III non –small cell lung cancer (NSCLC). It is unclear whether the results obtained as part of randomised controlled trials are a reflection of real-world (RW) data. Several questions remain unanswered with regard to RW durvalumab use, such as optimal time to durvalumab initiation, incidence of pneumoniti s and response in PD-L1 subgroups.

Source: European Journal of Cancer - November 24, 2020 Category: Cancer & Oncology Authors: Antoine Desilets, F élix Blanc-Durand, Sally Lau, Taiki Hakozaki, Rui Kitadai, Julie Malo, Wiam Belkaid, Corentin Richard, Meriem Messaoudene, Lena Cvetkovic, Suzanne Kazandjian, Mustapha Tehfe, Marie Florescu, Kevin Jao, Nathalie Daaboul, Scott Owen, Be Tags: Original Research Source Type: research